EGFR and breast cancer: Representing 15–20% of breast cancer cases, TNBC exhibits intrinsic resistant against targeted therapeutics for epidermal growth factor receptor (EGFR) and MET, despite their frequent amplification in TNBC [1,2,4,5,6,7,8,9,10,11,12].